Proteome Sciences (CHIX:PRML) Liabilities-to-Assets : 2.16 (As of Dec. 2025)


What is Proteome Sciences Liabilities-to-Assets?

Proteome Sciences CHIX:PRML +7.63% Liabilities-to-Assets is 2.16 as of Dec. 2025. The stock has 6 warning signs investors should review.

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. Proteome Sciences's Total Liabilities for the quarter that ended in Dec. 2025 was £17.79 Mil. Proteome Sciences's Total Assets for the quarter that ended in Dec. 2025 was £8.26 Mil. Therefore, Proteome Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 was 2.16.

Proteome Sciences  (CHIX:PRMl) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.

Proteome Sciences Liabilities-to-Assets Related Terms

Proteome Sciences Liabilities-to-Assets Historical Data

* Premium members only.

The historical data trend for Proteome Sciences's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Proteome Sciences Liabilities-to-Assets Chart

Proteome Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.28 1.07 1.27 1.73 2.16

Proteome Sciences Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.27 1.56 1.73 2.03 2.16

CHIX:PRML vs TMO, DHR, IDXX: Liabilities-to-Assets Comparison

For the Diagnostics & Research subindustry, Proteome Sciences's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Proteome Sciences Liabilities-to-Assets vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where Proteome Sciences's Liabilities-to-Assets falls into.


Proteome Sciences Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

Proteome Sciences's Liabilities-to-Assets Ratio for the fiscal year that ended in Dec. 2025 is calculated as:

Liabilities-to-Assets (A: Dec. 2025 )=Total Liabilities/Total Assets
=17.786/8.255
=2.15

Proteome Sciences's Liabilities-to-Assets Ratio for the quarter that ended in Dec. 2025 is calculated as

Liabilities-to-Assets (Q: Dec. 2025 )=Total Liabilities/Total Assets
=17.786/8.255
=2.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Liabilities-to-Assets →
What does a Liabilities-to-Assets of 2.16 mean?
Proteome Sciences (CHIX:PRML) has a Liabilities-to-Assets of 2.16 as of Dec. 2025. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Proteome Sciences and its competitors.
Is Proteome Sciences' Liabilities-to-Assets too high?
Proteome Sciences' current Liabilities-to-Assets is 2.16.
How does Proteome Sciences' Liabilities-to-Assets compare to TMO and DHR?
Proteome Sciences' Liabilities-to-Assets of 2.16 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Liabilities-to-Assets for a Medical Diagnostics & Research company?
A good Liabilities-to-Assets depends on the Medical Diagnostics & Research industry context. However, Liabilities-to-Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Liabilities-to-Assets mean?
A high Liabilities-to-Assets can signal that a stock is expensive relative to its fundamentals. Liabilities-to-Assets equals total liabilities divided by total assets. It measures financial leverage. View historical data on Proteome Sciences and its competitors. Proteome Sciences's current Liabilities-to-Assets is 2.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Modestly Undervalued. The stock's GF Value™ is £0.02, compared to a current price of £0.01 — trading 29.5% below its estimated fair value. The current Liabilities-to-Assets is 2.16. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Liabilities-to-Assets calculated?
Liabilities-to-Assets is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Liabilities-to-Assets is 2.16 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Proteome Sciences Business Description

Other Exchanges PRM:UKPI2:Germany
Address Downside Bridge Road, Coveham House, Cobham, Surrey, GBR, KT11 3EP
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.